ArticleDigestive diseases and sciences2016
Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials.
Article in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 85 citations in OpenAlex.
- A population pharmacokinetic-pharmacodynamic model of YH12852, a highly selective 5-hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation.CPT: pharmacometrics & systems pharmacology · 2021Trial
- Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.Alimentary pharmacology & therapeutics · 2020Trial
- Trial
- Pathophysiological mechanisms, diagnostic innovations, and multimodal therapeutic strategies for slow transit constipation.BMC gastroenterology · 2025Review
- Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride Initiation.Gastro hep advances · 2025Article
- A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States.Journal of managed care & specialty pharmacy · 2024Observational
- [The proven and the new in the pharmacotherapy of irritable bowel syndrome].Innere Medizin (Heidelberg, Germany) · 2024Review
- Idiopathic Slow Transit Constipation: Pathophysiology, Diagnosis, and Management.Medicina (Kaunas, Lithuania) · 2024Review
- Comparison of enteral prucaloprideFrontiers in pharmacology · 2024Article
- Preclinical pharmacokinetic studies and prediction of human PK profiles for Deg-AZM, a clinical-stage new transgelin agonist.Frontiers in pharmacology · 2024Article
- Efficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age, body mass index, and renal function: a post hoc analysis of phase III and IV, randomized, placebo-controlled clinical studies.Therapeutic advances in gastroenterology · 2024Article
- Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in pediatric patients with functional constipation.Contemporary clinical trials communications · 2023Article
- Interferential therapy for chronic constipation in adults: The CON-COUR randomizedcontrolled trial.United European gastroenterology journal · 2023Article
- Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.Arthritis care & research · 2022Article
- Medical Management of Constipation in Elderly Patients: Systematic Review.Journal of neurogastroenterology and motility · 2021Review
- Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders.Alimentary pharmacology & therapeutics · 2021Review
- Role of Prucalopride in Treating Functional Constipation and Gastroparesis: A Systemic Review.Cureus · 2021Review
- Action Mode of Gut Motility, Fluid and Electrolyte Transport in Chronic Constipation.Frontiers in pharmacology · 2021Review
- Microbial Profiles of Patients With Antipsychotic-Related Constipation Treated With Electroacupuncture.Frontiers in medicine · 2021Article
- Current Opinion on Prucalopride in Gastroparesis and Chronic Constipation Treatment: A Focus on Patient Selection and Safety.Therapeutics and clinical risk management · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrucalopride, a selective, high-affinity 5-hydroxytryptamine 4 receptor agonist, stimulates gastrointestinal and colonic motility and alleviates common symptoms of chronic constipation (CC) in adults. The relative efficacy by gender has not been evaluated.
aimTo evaluate the global efficacy and safety of prucalopride 2 mg daily in men and women with CC using data from six large, randomized, controlled clinical trials.
methodsData were combined from six phase 3 and 4, double-blind, randomized, placebo-controlled, parallel-group trials. The primary efficacy endpoint was the percentage of patients with a mean of ≥3 spontaneous complete bowel movements (SCBMs) per week over 12 weeks of treatment. Safety was assessed throughout all the trials.
resultsOverall, 2484 patients (597 men; 1887 women; prucalopride, 1237; placebo, 1247) were included in the integrated efficacy analysis and 2552 patients were included in the integrated safety analysis. Significantly more patients achieved a mean of ≥3 SCBMs/week over the 12 weeks of treatment in the prucalopride group (27.8 %) than in the placebo group [13.2 %, OR 2.68 (95 % CI 2.16, 3.33), p < 0.001]. Prucalopride had a favorable safety and tolerability profile. Efficacy and safety outcomes were not significantly different between men and women.
conclusionThe integrated analysis demonstrates the efficacy and safety of prucalopride in the treatment of CC in men and women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.